US Personalized Medicine Companies

Illumina acquired Grail, Inc. for $8 billion, aiming to strengthen its leadership in cancer genomics and early detection technologies.

Exact Sciences Corporation partnered with Tempus Labs, Inc. to combine their expertise in cancer diagnostics and data analytics, providing comprehensive personalized oncology solutions.

Verily Life Sciences LLC (Alphabet) collaborated with Johnson & Johnson to develop and deploy AI-powered tools for clinical trial matching and patient selection, facilitating personalized drug development.

Foundation Medicine launched its FoundationOne CDx tissue-based assay, enabling comprehensive genomic profiling of tumors for cancer treatment guidance and clinical trial eligibility.

Guardant Health introduced its LUNAR-Dx liquid biopsy test, offering non-invasive detection and monitoring of minimal residual disease in various cancers.

Adaptive Biotechnologies Corporation developed its clonoSEQ assay, providing insights into T-cell receptor (TCR) repertoire for personalized immunotherapy development in cancer and infectious diseases.

List of US Personalized Medicine Key Companies in the Market

• Laboratory Corporation of America


• Quest Diagnostics


• Abbott


• Becton Dickinson & Co.


• Siemens Healthcare Diagnostics Inc.


• GE Healthcare


• Pfizer Inc.


• Sanofi


• CardioDx Inc.


• Asuragen Inc.


• Bristol-Myers Squibb